Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 17 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cimetidine can dramatically increase survival of colorectal cancer patients

Cimetidine treatment dramatically improves survival in colorectal cancer patients with tumor cells expressing high levels of sialyl Lewis antigens X and A, according to a study published in the latest issue of the British Journal of Cancer.

News image

fiogf49gjkf04

A team from Nagoya, Japan, investigated the effects of cimetidine in colorectal cancer patients.

A total of 64 colorectal cancer patients, who received curative operation, were examined for the effects of cimetidine treatment on survival and recurrence.

The cimetidine group was given 800 mg of cimetidine per day orally, together with 200 mg of 5-fluorouracil per day. The control group received 5-fluorouracil alone.

Treatment was initiated 2 weeks after the operation and terminated after 1 year.

Robust beneficial effects of cimetidine were noted: the 10-year survival rate of the cimetidine group was 85%, whereas that of control group was 50%.

In previous studies, the authors observed that cimetidine blocked the expression of E-selectin on vascular endothelium and inhibited the adhesion of cancer cells to the endothelium. Thus, the researchers further stratified the patients according to the expression levels of sialyl Lewis antigens X (sLx) and A (sLa).

It was found that cimetidine treatment was particularly effective in patients whose tumor had higher sLx and sLa antigen levels.

10-year survival for patients with high sLx levels:
Cimetidine group: 96%
Controls: 35%
British Journal of Cancer

For example, higher CSLEX staining was used to recognize tumors expressing high levels of sLx antigens. The 10-year cumulative survival rate of these patients in the cimetidine group was 96%, whereas that of control group was 35%.

In contrast, in the group of patients with no or low levels of CSLEX staining, cimetidine did not show significant beneficial effect. Here the 10-year survival rate of the cimetidine group was 70% and that of the control group was 86%.

Dr S. Matsumoto, of the Fujita Health University in Nagoya, concluded on behalf of the group, "These results clearly indicate that cimetidine treatment dramatically improved survival in colorectal cancer patients with tumor cells expressing high levels of sLx and sLa."

In an accompanying Editorial, Drs D. Eaton and R. E. Hawkins, of Manchester, England, commented that these results were striking.

"The results appear to justify further investigation of the effect of cimetidine on E-selectin expression and the consequences of this interaction on sLx and sLa expressing colonic carcinoma," they said.

"Subsequent large-scale clinical trials appear warranted," they concluded.

Br J Cancer 2002; 86: 159-60, 161-7
06 February 2002

Go to top of page Email this page Email this page to a colleague

 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 20 December 2017 
Management of abnormal liver blood tests
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD
 13 December 2017 
Tryptophan metabolism and IBD activity
 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us